8:00 am Registration & Coffee

8:55 am Chair’s Opening Remarks

Trailblazing iPSC-Derived Therapies for Immuno-Oncology to Reaffirm Their Advantages

9:00 am Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future Outlook & Developments

  • Wei Li Chief Scientific Officer, Cytovia Therapeutics
  • Adrienne Farid Chief Operating Officer, Century Therapeutics
  • Xiaokui Zhang Chief Scientific Officer, Aspen Neuroscience
  • Gregory Fiore Chief Executive Officer, Exacis Biotherapeutics
  • David Main President & Chief Executive Officer, Notch Therapeutics


  • Reflecting on current learnings from therapy development to drive focus and motivation while highlighting demands of the future
  • Validating iPSCs as a starting material for immuno-oncology and regenerative medicine therapies to drive further investment and efforts in the space

10:00 am Morning Refreshment Break & Speed Networking

11:00 am Gamma Delta iPSC as a Strategy to Increase Depth of Response in the Allogeneic Setting

  • Lawrence Lamb Chief Scientific Officer & Executive Vice President, IN8Bio


  • Persistence of allogeneic cell products is limited by depth and duration of lymphodepletion
  • Engineered allo-evasion is a potential strategy requiring deep editing and upgraded safety measures
  • Multiple dosing at high effector numbers customized for the malignancy is an alternative strategy for tumor eradication and prolonger CR

11:30 am iPSC-Derived Blood Lineages for IO applications

  • George Daley Dean of Faculty of Medicine, Harvard Medical School


  • Describe strategies for overcoming barriers to producing functional, developmentally mature blood lineages from embryonic cell sources
  • Describe genetic and chemical screens that identify mechanisms for directing lymphoid cell fates
  • Characterization of lymphocyte and NK cell subsets and applications in immune-oncology

12:00 pm Lunch Break & Networking


Turbocharging Gene Editing to Boost iPSC Therapies While Redefining Safety

1:30 pm Boosting Genetic Engineering of iPSCs to Prevent Genetic Instability


  • Maximizing on-target editing to ensure higher yields of stable cells
  • Improving efficiencies of multiplex targeting to reduce genetic variation
  • Distinguishing the optimal time to edit iPSC cells to enhance editing efficiency

2:00 pm Panel:Reviewing Methods to Editing iPSCs to Increase Therapy Persistence & Cell Retention in vivo

  • Xi Shi Associate Director, Platform Design & Genetic Engineering, Oncology Cell Therapies, Takeda
  • Ryan Crisman Co-Founder & Chief Technical Officer, Umoja Biopharma
  • Gregory Fiore Chief Executive Officer, Exacis Biotherapeutics


  • Discussing how to increase cell survival to produce effective regenerative cell replacement therapies
  • Assessing methods to ensure iPSC therapies for immunology persist long enough for effective tumor killing
  • Does administration of the cell therapy affect retention in the body?


Leveraging Scalable Expansion of iPSCs to Advance Manufacturing Processes

1:30 pm Scalable Manufacture of CAR-NK Cells from Engineered Pluripotent Stem Cells with 3-D Bioreactor

  • John Lu President & Chief Executive Officer, HebeCell


  • A proprietary scalable 3D iPS-NK manufacture platform with defined, serum-free and feeder-free conditions: pure and strong functional iPS-NK with CD8+ effector cell identity for immunotherapy
  • Establishment of permanent, stable, genetically-engineered and clonal iPS-CAR lines for the manufacture of unlimited homogenous CAR-NK cells from multiple master iPS-CAR cell banks
  • Development of next-generation 3D bioreactor platform and logistics: the ultimate goal of making CAR-NK products affordable and available for ordinary patients

2:00 pm Panel: Points to Consider When Preparing for Scale-Up to Drive Efficient Transfer to the Clinic & Commercialization


  • Reflecting on the manufacturability of products to aid in scale-up of therapy
  • Examining future demands of commercialization to adjust current processes before it’s too late
  • Collaborating to identify the future needs of technology to master scalable iPSC products

3:00 pm Afternoon Refreshments & Poster Session

4:00 pm Engineering an Autologous iPSC Therapy for Limb-Girdle Muscular Dystrophy

  • Peter Andersen Co-Founder & Chief Scientific Officer, Vita Therapeutics


  • Successful gene replacement
  • Safe and efficient genome editing
  • Tackling GMP Manufacturing

Exploiting iPSC Product Potency to Maximize Therapeutic Efficacy

4:30 pm Enhancing the Cytotoxic Anti-Tumor Activity of iNK Cell Therapy Using a Flex-NK™ Cell Engager

  • Daniel Teper Co-Founder & Chief Executive Officer, Cytovia Therapeutics


  • Flex NK Cell Engager antibodies redirect NK cells to kill target tumor cells
  • Flex NK cell Engager antibodies enhance the cytotoxicity of PBNK cells as well as iPSC derived NK cells (iNKs)
  • Pre-clinical data supports initiation of clinical trials in both hematological malignancies and solid tumors

4:00 pm Developing a Best Practice Directed Differentiation Protocol to Efficiently Produce a Patient Friendly iPSC Product

  • Rita Perlingeiro Professor of Medicine, Cardiovascular Division, University of Minnesota


  • Establishing robust and scalable differentiation processes to ensure optimal development
  • Ensuring differentiation protocol generates a safe cell product
  • Establishing a differentiation protocol that is reproducible to facilitate and accelerate cell production as well as testing

Leveraging Potency Assays to Benchmark Product Efficacy

4:30 pm Establishing Effective Potency Assays to Test Therapy Efficacy


  • Identifying markers and characteristics that predict clinical effectiveness to measure in assays
  • Establishing potency assays to assess the actions and functions of iPSC products to safeguard cell activity
  • Certifying that iPSC products have potency levels of original cells through assays

5:00 pm Chair’s Closing Remarks

5:05 pm Close of Conference Day One